MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599236 | Name: Tolrestat
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolrestat is a Aldose Reductase inhibitor.

Chemical Structure

Tolrestat
CAS#82964-04-3

Theoretical Analysis

MedKoo Cat#: 599236

Name: Tolrestat

CAS#: 82964-04-3

Chemical Formula: C16H14F3NO3S

Exact Mass: 357.0646

Molecular Weight: 357.34

Elemental Analysis: C, 53.78; H, 3.95; F, 15.95; N, 3.92; O, 13.43; S, 8.97

Price and Availability

Size Price Availability Quantity
10mg USD 325.00 2 Weeks
25mg USD 680.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AY 27773; AY-27773; AY27773; Tolrestat; AY-27,773; AY 27,773; AY27,773; Alredase; Tolrestatum; Lorestat;
IUPAC/Chemical Name
N-(6-methoxy-5-(trifluoromethyl)naphthalene-1-carbonothioyl)-N-methylglycine
InChi Key
LUBHDINQXIHVLS-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)
SMILES Code
O=C(O)CN(C(C1=C2C=CC(OC)=C(C(F)(F)F)C2=CC=C1)=S)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 357.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications. 1993 Jul-Sep;7(3):170-8. PubMed PMID: 8343611. 2: Fabiani F, De Vincentis N, Staffilano A. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Diabete Metab. 1995 Dec;21(5):360-4. PubMed PMID: 8586153. 3: Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L, Ceriello A, Quatraro A, D'Onofrio F. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care. 1995 Apr;18(4):536-41. PubMed PMID: 7497865. 4: Cayen MN, Hicks DR, Ferdinandi ES, Kraml M, Greselin E, Dvornik D. Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeys. Drug Metab Dispos. 1985 Jul-Aug;13(4):412-9. PubMed PMID: 2863103. 5: Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med. 1993 Jan 1;118(1):7-11. PubMed PMID: 8416161. 6: McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG Jr. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia. 1991 Oct;34(10):695-701. PubMed PMID: 1959701. 7: Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diabetes Complications. 1993 Jul-Sep;7(3):157-69. PubMed PMID: 8343610. 8: van Gerven JM, Lemkes HH, van Dijk JG. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. J Diabetes Complications. 1992 Jan-Mar;6(1):45-8. PubMed PMID: 1562758. 9: Daniele E, Coco MP. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]. Clin Ter. 1995 Dec;146(12):793-99. Review. Italian. PubMed PMID: 8681499. 10: Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism. 1985 Oct;34(10):885-92. PubMed PMID: 3930915. 11: Macleod AF, Boulton AJ, Owens DR, Van Rooy P, Van Gerven JM, Macrury S, Scarpello JH, Segers O, Heller SR, Van Der Veen EA. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabete Metab. 1992 Jan-Feb;18(1):14-20. PubMed PMID: 1563531. 12: van Griensven JM, Jusko WJ, Lemkes HH, Kroon R, Verhorst CJ, Chiang ST, Cohen AF. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther. 1995 Dec;58(6):631-40. PubMed PMID: 8529328. 13: Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990 Jul;33(7):431-7. PubMed PMID: 2119323. 14: McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabet Complications. 1988 Jan-Mar;2(1):16-8. PubMed PMID: 2968349. 15: McAuliffe AV, Brooks BA, Fisher EJ, Molyneaux LM, Yue DK. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion. Nephron. 1998 Nov;80(3):277-84. PubMed PMID: 9807036. 16: Calcutt NA, McMurray HF, Moorhouse DF, Bache M, Parthasarathy S, Powell HC, Mizisin AP. Inhibition of macrophage chemotaxis and peripheral nerve regeneration in normal and hyperglycemic rats by the aldose reductase inhibitor Tolrestat. Exp Neurol. 1994 Aug;128(2):226-32. PubMed PMID: 8076666. 17: Troy SM, Hicks DR, Kraml M, Conrad K, Chiang ST. The effect of renal disease on tolrestat pharmacokinetics. Clin Pharmacol Ther. 1992 Mar;51(3):271-7. PubMed PMID: 1544287. 18: Lee YJ, Lee HK. Degradation kinetics of tolrestat. J Pharm Sci. 1990 Jul;79(7):628-33. PubMed PMID: 2398472. 19: Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem Cell Biol. 1996;74(3):355-62. PubMed PMID: 8883841. 20: Raskin P, Rosenstock J, Challis P, Ryder S, Mullane JF, Gonzalez R, Hicks D, Smith T, Dvornik D. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clin Pharmacol Ther. 1985 Dec;38(6):625-30. PubMed PMID: 4064465.

View History

Tolperisone free base

Tolperisone free base

NKI-42008 chloride

NKI-42008 chloride

Tolpyrramide

Tolpyrramide